<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600882</url>
  </required_header>
  <id_info>
    <org_study_id>STP1-C002</org_study_id>
    <nct_id>NCT04600882</nct_id>
  </id_info>
  <brief_title>Characterization of a Clinical Subpopulation in Children With Autism Spectrum Disorder</brief_title>
  <official_title>Characterization of a Clinical Subpopulation in Children With Autism Spectrum Disorder (ASD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stalicla SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stalicla SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-center, observational study is being conducted to identify a well-characterized&#xD;
      subgroup within the ASD patient population, based on clinical symptoms and biosample&#xD;
      analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects enrolled&#xD;
  </why_stopped>
  <start_date type="Anticipated">November 30, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of non-behavioral phenotypical traits in sub-populations with Autism Spectrum Disorder (ASD)</measure>
    <time_frame>Day 0</time_frame>
    <description>A questionnaire will be administered to collect non-behavioral traits and co-occurring conditions data of the participants</description>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Nationwide Children's Hospital Primary Care Clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed with ASD (based on DSM-5 criteria and supported by either ADI-R&#xD;
             or ADOS-2 scores)&#xD;
&#xD;
          -  At least two well documented head circumference values recorded within the first 2&#xD;
             years of life&#xD;
&#xD;
          -  Participants must have a parent or reliable caregiver who agrees to provide&#xD;
             information about the participant as required by the protocol and should be fluent in&#xD;
             English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Genetically identified ASD (syndromic form of autism, e.g. fragile X)&#xD;
&#xD;
          -  Episode of fever (i.e. ≥100.5 °F) or clinically significant illness without fever (as&#xD;
             judged by the Investigator), within 10 days before the study visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autism spectrum disorder</keyword>
  <keyword>endophenotyping</keyword>
  <keyword>observational</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

